Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis.
Standard
Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. / Bechdolf, Andreas; Müller, Hendrik; Stützer, Hartmut; Wagner, Michael; Maier, Wolfgang; Lautenschlager, Marion; Heinz, Andreas; de Millas, Walter; Janssen, Birgit; Gaebel, Wolfgang; Michel, Tanja Maria; Schneider, Frank; Lambert, Martin; Naber, Dieter; Brüne, Martin; Krüger-Özgürdal, Seza; Wobrock, Thomas; Riedel, Michael; Klosterkötter, Joachim; Group, PREVENT Study.
In: SCHIZOPHRENIA BULL, Vol. 37 Suppl 2, 2011, p. 111-121.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis.
AU - Bechdolf, Andreas
AU - Müller, Hendrik
AU - Stützer, Hartmut
AU - Wagner, Michael
AU - Maier, Wolfgang
AU - Lautenschlager, Marion
AU - Heinz, Andreas
AU - de Millas, Walter
AU - Janssen, Birgit
AU - Gaebel, Wolfgang
AU - Michel, Tanja Maria
AU - Schneider, Frank
AU - Lambert, Martin
AU - Naber, Dieter
AU - Brüne, Martin
AU - Krüger-Özgürdal, Seza
AU - Wobrock, Thomas
AU - Riedel, Michael
AU - Klosterkötter, Joachim
AU - Group, PREVENT Study
PY - 2011
Y1 - 2011
N2 - Antipsychotics, cognitive behavioral therapy (CBT), and omega-3-fatty acids have been found superior to control conditions as regards prevention of psychosis in people at-risk of first-episode psychosis. However, no large-scale trial evaluating the differential efficacy of CBT and antipsychotics has been performed yet. In PREVENT, we evaluate CBT, aripiprazole, and clinical management (CM) as well as placebo and CM for the prevention of psychosis in a randomized, double-blind, placebo-controlled trial with regard to the antipsychotic intervention and a randomized controlled trial with regard to the CBT intervention with blinded ratings. The hypotheses are first that CBT and aripiprazole and CM are superior to placebo and CM and second that CBT is not inferior to aripiprazole and CM combined. The primary outcome is transition to psychosis. By November 2010, 156 patients were recruited into the trial. The subjects were substantially functionally compromised (Social and Occupational Functioning Assessment Scale mean score 52.5) and 78.3% presented with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition axis I comorbid diagnosis. Prior to randomization, 51.5% of the participants preferred to be randomized into the CBT arm, whereas only 12.9% preferred pharmacological treatment. First, assessments of audiotaped treatment sessions confirmed the application of CBT-specific skills in the CBT condition and the absence of those in CM. The overall quality rating of the CBT techniques applied in the CBT condition was good. When the final results of the trial are available, PREVENT will substantially expand the current limited evidence base for best clinical practice in people at-risk (prodromal) of first-episode psychosis.
AB - Antipsychotics, cognitive behavioral therapy (CBT), and omega-3-fatty acids have been found superior to control conditions as regards prevention of psychosis in people at-risk of first-episode psychosis. However, no large-scale trial evaluating the differential efficacy of CBT and antipsychotics has been performed yet. In PREVENT, we evaluate CBT, aripiprazole, and clinical management (CM) as well as placebo and CM for the prevention of psychosis in a randomized, double-blind, placebo-controlled trial with regard to the antipsychotic intervention and a randomized controlled trial with regard to the CBT intervention with blinded ratings. The hypotheses are first that CBT and aripiprazole and CM are superior to placebo and CM and second that CBT is not inferior to aripiprazole and CM combined. The primary outcome is transition to psychosis. By November 2010, 156 patients were recruited into the trial. The subjects were substantially functionally compromised (Social and Occupational Functioning Assessment Scale mean score 52.5) and 78.3% presented with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition axis I comorbid diagnosis. Prior to randomization, 51.5% of the participants preferred to be randomized into the CBT arm, whereas only 12.9% preferred pharmacological treatment. First, assessments of audiotaped treatment sessions confirmed the application of CBT-specific skills in the CBT condition and the absence of those in CM. The overall quality rating of the CBT techniques applied in the CBT condition was good. When the final results of the trial are available, PREVENT will substantially expand the current limited evidence base for best clinical practice in people at-risk (prodromal) of first-episode psychosis.
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - Adolescent
KW - Young Adult
KW - Treatment Outcome
KW - Double-Blind Method
KW - Placebos
KW - Piperazines/therapeutic use
KW - Antipsychotic Agents/therapeutic use
KW - Cognitive Therapy/methods
KW - Combined Modality Therapy/methods
KW - Early Medical Intervention/methods
KW - Psychotic Disorders/drug therapy/prevention & control/therapy
KW - Quinolones/therapeutic use
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - Adolescent
KW - Young Adult
KW - Treatment Outcome
KW - Double-Blind Method
KW - Placebos
KW - Piperazines/therapeutic use
KW - Antipsychotic Agents/therapeutic use
KW - Cognitive Therapy/methods
KW - Combined Modality Therapy/methods
KW - Early Medical Intervention/methods
KW - Psychotic Disorders/drug therapy/prevention & control/therapy
KW - Quinolones/therapeutic use
M3 - SCORING: Journal article
VL - 37 Suppl 2
SP - 111
EP - 121
JO - SCHIZOPHRENIA BULL
JF - SCHIZOPHRENIA BULL
SN - 0586-7614
ER -